Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Microrheological Method Determines Blood Type

By LabMedica International staff writers
Posted on 13 Aug 2013
The development of microfluidic blood-typing assays can reduce the time of analysis, and enable simultaneous determination of the most clinically important antigens. More...


A method for typing and subtyping blood has been developed in a simple microfluidic system that monitors the speed of flow of microdroplets and determining agglutination in small samples of liquid.

Scientists at the Institute of Physical Chemistry of the Polish Academy of Sciences (Warsaw, Poland) have demonstrated a microfluidic method for reproducible and objective determination of agglutination in small, nanoliter quantities of liquid. They demonstrated the reliability of the method on the model example of determination of blood type, yet the method should also be possible to use with the wide range of agglutination assays used in in vitro diagnostics.

The investigators tested agglutination in droplets with A, B and O blood groups, and then a second series of agglutination test in droplets with different Rh factors. Each series was performed for both standardized red blood cells and human blood samples. The red blood cells were not removed from the whole blood before these tests. In each series a droplet with antibodies was linked in the merging chamber with a droplet containing red blood cells. The merging chamber was equipped with two electrodes connected to a source of alternating current (AC) electrostatic potential. An oscillating electric field speeds up the coalescence of droplets arriving from the individual T-junctions. A created droplet was sent to the section of measurement for the time of flow.

The method had a very high sensitivity and reliability. The reliability approached 100% with an estimated chance of mistyping on the order of one per million samples. The method of detection of agglutination could potentially be used for automating various agglutination assays. The authors noted that the method offers the potential benefits of a reduction of the volume of blood sample to single microliters for the whole test, the lack of requirement for preprocessing such as centrifugation, and eliminating any subjectivity from the procedure.

Importantly, the method could be compliant both with a point-of-care format for the simplest blood-typing protocols and with multiplexed assays for complex analyses, such as cross-match testing or other multiple antigen determinations in a bench-top format. The study was published on June 18, 2013, in the journal Lab on a Chip.

Related Links:
Polish Institute of Physical Chemistry


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
Thyroid Test
Anti-Thyroid EIA Test
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.